Replies to post #95818 on Biotech Values

[DewDiligence]

ACHN:

With respect to the long half-life being more of a negative than a positive, isn't this really only an issue if the drug does turn out to have some legitimate safety issues (which we haven't seen to date)?

All antiviral drugs cause adverse events in some patients, and hence a drug’s having a very long half-life could make docs less inclined to prescribe it. It follows that prospective partners might be less inclined to license it.